116 related articles for article (PubMed ID: 22647228)
1. [Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?].
Linn-Rasker SP; van Albada-Kuipers GA; Dubois SV; Janssen K; Zweers PG
Ned Tijdschr Geneeskd; 2012; 156(22):A4464. PubMed ID: 22647228
[TBL] [Abstract][Full Text] [Related]
2. Merkel cell carcinoma in a patient treated with adalimumab: case report.
Krishna SM; Kim CN
Cutis; 2011 Feb; 87(2):81-4. PubMed ID: 21416774
[TBL] [Abstract][Full Text] [Related]
3. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
[TBL] [Abstract][Full Text] [Related]
5. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
[No Abstract] [Full Text] [Related]
7. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
8. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
9. Anti-TNF-alpha therapies: they are all the same (aren't they?).
Mpofu S; Fatima F; Moots RJ
Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
[No Abstract] [Full Text] [Related]
10. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
Actis GC; Lagget M; Pellicano R; Rosina F
Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
[No Abstract] [Full Text] [Related]
11. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
[No Abstract] [Full Text] [Related]
12. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
Kekow J; Welte T; Kellner U; Pap T
Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
[No Abstract] [Full Text] [Related]
13. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
15. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
Hyrich KL; Silman AJ
J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
[No Abstract] [Full Text] [Related]
17. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F; Sarzi-Puttini P; Botsios C; Carletto A; Cipriani P; Favalli EG; Frati E; Foschi V; Gasparini S; Giardina A; Gremese E; Iannone F; Sebastiani M; Ziglioli T; Biasi D; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Gorla R; Govoni M; Lapadula G; Marchesoni A; Salaffi F; Punzi L; Triolo G; Ferraccioli G
Autoimmun Rev; 2012 Dec; 12(2):225-9. PubMed ID: 22796281
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
Fernández-Nebro A; Irigoyen MV; Ureña I; Belmonte-López MA; Coret V; Jiménez-Núñez FG; Díaz-Cordovés G; López-Lasanta MA; Ponce A; Rodríguez-Pérez M; Calero E; González-Santos P
J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
[TBL] [Abstract][Full Text] [Related]
19. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
[TBL] [Abstract][Full Text] [Related]
20. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
